by Truveta Research | Sep 5, 2025 | Research, Research Insights
In July 2025, following the CVS formulary change, 9.6% of patients on AOM tirzepatide switched to a different drug. This was more than a 16-fold increase compared with the average earlier in the year. Among AOM tirzepatide users who switched to a different GLP-1...
by Truveta Research | Sep 5, 2025 | Research, Research Insights
AOM tirzepatide prescriptions rates, which had been rising by an average of +0.06 percentage points per month (Jan 2024–Jun 2025), grew only +0.03 points from June to July 2025 after the CVS GLP-1 formulary change. In contrast, AOM semaglutide increased by +0.1 points...
